OMERACT-based fibromyalgia symptom subgroups: an exploratory cluster analysis

  • Ann Vincent
  • Tanya L Hoskin
  • Mary O Whipple
  • Daniel J Clauw
  • Debra L Barton
  • Roberto P Benzo
  • David A Williams
Research article

Abstract

Introduction

The aim of this study was to identify subsets of patients with fibromyalgia with similar symptom profiles using the Outcome Measures in Rheumatology (OMERACT) core symptom domains.

Methods

Female patients with a diagnosis of fibromyalgia and currently meeting fibromyalgia research survey criteria completed the Brief Pain Inventory, the 30-item Profile of Mood States, the Medical Outcomes Sleep Scale, the Multidimensional Fatigue Inventory, the Multiple Ability Self-Report Questionnaire, the Fibromyalgia Impact Questionnaire-Revised (FIQ-R) and the Short Form-36 between 1 June 2011 and 31 October 2011. Hierarchical agglomerative clustering was used to identify subgroups of patients with similar symptom profiles. To validate the results from this sample, hierarchical agglomerative clustering was repeated in an external sample of female patients with fibromyalgia with similar inclusion criteria.

Results

A total of 581 females with a mean age of 55.1 (range, 20.1 to 90.2) years were included. A four-cluster solution best fit the data, and each clustering variable differed significantly (P <0.0001) among the four clusters. The four clusters divided the sample into severity levels: Cluster 1 reflects the lowest average levels across all symptoms, and cluster 4 reflects the highest average levels. Clusters 2 and 3 capture moderate symptoms levels. Clusters 2 and 3 differed mainly in profiles of anxiety and depression, with Cluster 2 having lower levels of depression and anxiety than Cluster 3, despite higher levels of pain. The results of the cluster analysis of the external sample (n = 478) looked very similar to those found in the original cluster analysis, except for a slight difference in sleep problems. This was despite having patients in the validation sample who were significantly younger (P <0.0001) and had more severe symptoms (higher FIQ-R total scores (P = 0.0004)).

Conclusions

In our study, we incorporated core OMERACT symptom domains, which allowed for clustering based on a comprehensive symptom profile. Although our exploratory cluster solution needs confirmation in a longitudinal study, this approach could provide a rationale to support the study of individualized clinical evaluation and intervention.

Keywords

Fibromyalgia Fibromyalgia Impact Questionnaire Brief Pain Inventory Multidimensional Fatigue Inventory Mental Composite Score 

Abbreviations

BMI

Body mass index

BPI

Brief Pain Inventory

FIQ-R

Revised Fibromyalgia Impact Questionnaire

FM

Fibromyalgia

GAD-7

Generalized Anxiety Disorder 7-item scale

MASQ

Multiple Ability Self-report Questionnaire

MFI

Multidimensional Fatigue Inventory

MOS-Sleep

Medical Outcomes Study Sleep Scale

OMERACT

Outcome Measures in Rheumatology

PHQ-9

Patient Health Questionnaire

POMS

Profile of Mood States

SF-36

36-item Short Form survey

SNRI

Serotonin norepinephrine reuptake inhibitor

SS

Symptom severity

SSRI

Selective serotonin reuptake inhibitor

WPI

Widespread Pain Index

Notes

Acknowledgements

This study was supported in part by the Center for Translational Science Activities (CTSA) at the Mayo Clinic. This center is funded in part by a grant from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) (RR024150). The manuscript contents are solely the responsibility of the authors and do not necessarily represent the official views of CTSA, NCRR or NIH. The funders had no role in the study design, data collection and analysis, decision to publish or manuscript preparation. The study data were collected and managed using REDCap electronic data capture tools hosted at the Mayo Clinic. REDCap (Research Electronic Data Capture) is a secure, web-based application designed to support data capture for research studies by providing (1) an intuitive interface for validated data entry, (2) audit trails for tracking data manipulation and export procedures, (3) automated export procedures for seamless data downloads to common statistical packages and (4) procedures for importing data from external sources.

Supplementary material

13075_2014_463_MOESM1_ESM.gif (49 kb)
Authors’ original file for figure 1
13075_2014_463_MOESM2_ESM.tiff (1.5 mb)
Authors’ original file for figure 2
13075_2014_463_MOESM3_ESM.jpeg (42 kb)
Authors’ original file for figure 3

References

  1. 1.
    Fibromyalgia: poorly understood; treatments are disappointing.Prescrire Int 2009, 18:169-173.,Google Scholar
  2. 2.
    Clauw DJ, Arnold LM, McCarberg BH: The science of fibromyalgia. Mayo Clin Proc. 2011, 86: 907-911. 10.4065/mcp.2011.0206.CrossRefPubMedCentralPubMedGoogle Scholar
  3. 3.
    Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB: The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010, 62: 600-610. 10.1002/acr.20140.CrossRefGoogle Scholar
  4. 4.
    Bennett RM, Russell J, Cappelleri JC, Bushmakin AG, Zlateva G, Sadosky A: Identification of symptom and functional domains that fibromyalgia patients would like to see improved: a cluster analysis. BMC Musculoskelet Disord. 2010, 11: 134-10.1186/1471-2474-11-134.CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    de Souza JB, Goffaux P, Julien N, Potvin S, Charest J, Marchand S: Fibromyalgia subgroups: profiling distinct subgroups using the Fibromyalgia Impact Questionnaire: a preliminary study. Rheumatol Int. 2009, 29: 509-515. 10.1007/s00296-008-0722-5.CrossRefPubMedGoogle Scholar
  6. 6.
    Giesecke T, Williams DA, Harris RE, Cupps TR, Tian X, Tian TX, Gracely RH, Clauw DJ: Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum. 2003, 48: 2916-2922. 10.1002/art.11272.CrossRefPubMedGoogle Scholar
  7. 7.
    Loevinger BL, Shirtcliff EA, Muller D, Alonso C, Coe CL: Delineating psychological and biomedical profiles in a heterogeneous fibromyalgia population using cluster analysis. Clin Rheumatol. 2012, 31: 677-685. 10.1007/s10067-011-1912-1.CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.
    Rutledge DN, Mouttapa M, Wood PB: Symptom clusters in fibromyalgia: potential utility in patient assessment and treatment evaluation. Nurs Res. 2009, 58: 359-367. 10.1097/NNR.0b013e3181b499d2.CrossRefPubMedGoogle Scholar
  9. 9.
    Verra ML, Angst F, Brioschi R, Lehmann S, Keefe FJ, Staal JB, de Bie RA, Aeschlimann A: Does classification of persons with fibromyalgia into Multidimensional Pain Inventory subgroups detect differences in outcome after a standard chronic pain management program?. Pain Res Manag. 2009, 14: 445-453.PubMedCentralPubMedGoogle Scholar
  10. 10.
    Wilson HD, Robinson JP, Turk DC: Toward the identification of symptom patterns in people with fibromyalgia. Arthritis Rheum. 2009, 61: 527-534. 10.1002/art.24163.CrossRefPubMedCentralPubMedGoogle Scholar
  11. 11.
    Docampo E, Collado A, Escaramís G, Carbonell J, Rivera J, Vidal J, Alegre J, Rabionet R, Estivill X: Cluster analysis of clinical data identifies fibromyalgia subgroups. PLoS One. 2013, 8: e74873-10.1371/journal.pone.0074873.CrossRefPubMedCentralPubMedGoogle Scholar
  12. 12.
    Turk DC, Okifuji A, Sinclair JD, Starz TW: Differential responses by psychosocial subgroups of fibromyalgia syndrome patients to an interdisciplinary treatment. Arthritis Care Res. 1998, 11: 397-404. 10.1002/art.1790110511.CrossRefPubMedGoogle Scholar
  13. 13.
    Mease PJ, Arnold LM, Crofford LJ, Williams DA, Russell IJ, Humphrey L, Abetz L, Martin SA: Identifying the clinical domains of fibromyalgia: contributions from clinician and patient Delphi exercises. Arthritis Rheum. 2008, 59: 952-960. 10.1002/art.23826.CrossRefPubMedGoogle Scholar
  14. 14.
    Whipple MO, McAllister SJ, Oh TH, Luedtke CA, Toussaint LL, Vincent A: Construction of a US fibromyalgia registry using the Fibromyalgia Research Survey criteria. Clin Trans Sci. 2013, 6: 398-399. 10.1111/cts.12056.CrossRefGoogle Scholar
  15. 15.
    Cleeland CS, Ryan KM: Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994, 23: 129-138.PubMedGoogle Scholar
  16. 16.
    McNair DM, Lorr M, Droppleman LF: EdITS Manual for the Profile of Mood States. 1992, Educational and Industrial Testing Service, San Diego, CAGoogle Scholar
  17. 17.
    Cappelleri JC, Bushmakin AG, McDermott AM, Dukes E, Sadosky A, Petrie CD, Martin S: Measurement properties of the medical outcomes study sleep scale in patients with fibromyalgia. Sleep Med. 2009, 10: 766-770. 10.1016/j.sleep.2008.09.004.CrossRefPubMedGoogle Scholar
  18. 18.
    Smets EM, Garssen B, Bonke B, De Haes JC: The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995, 39: 315-325. 10.1016/0022-3999(94)00125-O.CrossRefPubMedGoogle Scholar
  19. 19.
    Seidenberg M, Haltiner A, Taylor MA, Hermann BB, Wyler A: Development and validation of a Multiple Ability Self-Report Questionnaire. Clin Exp Neuropsychol. 1994, 16: 93-104. 10.1080/01688639408402620.CrossRefGoogle Scholar
  20. 20.
    Bennett RM, Friend R, Jones KD, Ward R, Han BK, Ross RL: The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther. 2009, 11: R120-10.1186/ar2783.CrossRefPubMedCentralPubMedGoogle Scholar
  21. 21.
    Ware JE: SF-36 health survey update. Spine. 2000, 25: 3130-3139. 10.1097/00007632-200012150-00008.CrossRefPubMedGoogle Scholar
  22. 22.
    Williams DA, Arnold LM: Measures of fibromyalgia: Fibromyalgia Impact Questionnaire (FIQ), Brief Pain Inventory (BPI), Multidimensional Fatigue Inventory (MFI-20), Medical Outcomes Study (MOS) Sleep Scale, and Multiple Ability Self-Report Questionnaire (MASQ). Arthritis Care Res. 2011, 63: S86-S97. 10.1002/acr.20531.CrossRefGoogle Scholar
  23. 23.
    Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB: Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol. 2011, 38: 1113-1122. 10.3899/jrheum.100594.CrossRefPubMedGoogle Scholar
  24. 24.
    Aparicio VA, Ortega FB, Carbonell-Baeza A, Femia P, Tercedor P, Ruiz JR, Delgado-Fernández M: Are there gender differences in quality of life and symptomatology between fibromyalgia patients?. Am J Mens Health. 2012, 6: 314-319. 10.1177/1557988312436872.CrossRefPubMedGoogle Scholar
  25. 25.
    Buskila D, Neumann L, Alhoashle A, Abu-Shakra M: Fibromyalgia syndrome in men. Semin Arthritis Rheum. 2000, 30: 47-51. 10.1053/sarh.2000.8363.CrossRefPubMedGoogle Scholar
  26. 26.
    Castro-Sánchez AM, Matarán-Peñarrocha GA, López-Rodríguez MM, Lara-Palomo IC, Arendt-Nielsen L, Fernández-de-las-Peñas C: Gender differences in pain severity, disability, depression, and widespread pressure pain sensitivity in patients with fibromyalgia syndrome without comorbid conditions. Pain Med. 2012, 13: 1639-1647. 10.1111/j.1526-4637.2012.01523.x.CrossRefPubMedGoogle Scholar
  27. 27.
    Hooten WM, Townsend CO, Decker PA: Gender differences among patients with fibromyalgia undergoing multidisciplinary pain rehabilitation. Pain Med. 2007, 8: 624-632. 10.1111/j.1526-4637.2006.00202.x.CrossRefPubMedGoogle Scholar
  28. 28.
    Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford LJ, Glass JM, Martin SA, Morea J, Simon L, Strand CV, Williams DA: Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol. 2009, 36: 2318-2329. 10.3899/jrheum.090367.CrossRefPubMedCentralPubMedGoogle Scholar
  29. 29.
    Cleeland CS: The Brief Pain Inventory: User Guide. 2009, Charles S Cleeland, Houston, TXGoogle Scholar
  30. 30.
    Arnold LM, Rosen A, Pritchett YL, D’Souza DN, Goldstein DJ, Iyengar S, Wernicke JF: A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005, 119: 5-15. 10.1016/j.pain.2005.06.031.CrossRefPubMedGoogle Scholar
  31. 31.
    Chappell AS, Bradley LA, Wiltse C, Detke MJ, D’Souza DN, Spaeth M: A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med. 2008, 1: 91-102. 10.2147/IJGM.S3979.CrossRefPubMedCentralPubMedGoogle Scholar
  32. 32.
    Mease PJ, Spaeth M, Clauw DJ, Arnold LM, Bradley LA, Russell IJ, Kajdasz DK, Walker DJ, Chappell AS: Estimation of minimum clinically important difference for pain in fibromyalgia. Arthritis Care Res. 2011, 63: 821-826. 10.1002/acr.20449.CrossRefGoogle Scholar
  33. 33.
    Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, Walker DJ, Chappell AS, Arnold LM: Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain. 2008, 136: 432-444. 10.1016/j.pain.2008.02.024.CrossRefPubMedGoogle Scholar
  34. 34.
    Bourgeois A, LeUnes A, Meyers M: Full-scale and short-form of the Profile of Mood States: a factor analytic comparison. J Sport Behav. 2010, 33: 355-376.Google Scholar
  35. 35.
    Malin K, Littlejohn GO: Psychological control is a key modulator of fibromyalgia symptoms and comorbidities. J Pain Res. 2012, 5: 463-471.PubMedCentralPubMedGoogle Scholar
  36. 36.
    Katz RS, Heard AR, Mills M, Leavitt F: The prevalence and clinical impact of reported cognitive difficulties (fibrofog) in patients with rheumatic disease with and without fibromyalgia. J Clin Rheumatol. 2004, 10: 53-58. 10.1097/01.rhu.0000120895.20623.9f.CrossRefPubMedGoogle Scholar
  37. 37.
    Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP, Sharma U, Martin SA, Barrett JA, Haig G: A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008, 9: 792-805. 10.1016/j.jpain.2008.03.013.CrossRefPubMedGoogle Scholar
  38. 38.
    Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, Young JP, LaMoreaux LK, Martin SA, Sharma U: Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005, 52: 1264-1273. 10.1002/art.20983.CrossRefPubMedGoogle Scholar
  39. 39.
    Martin S, Chandran A, Zografos L, Zlateva G: Evaluation of the impact of fibromyalgia on patients' sleep and the content validity of two sleep scales. Health Qual Life Outcomes. 2009, 7: 64-10.1186/1477-7525-7-64.CrossRefPubMedCentralPubMedGoogle Scholar
  40. 40.
    Lin JMS, Brimmer DJ, Maloney EM, Nyarko E, BeLue R, Reeves WC: Further validation of the Multidimensional Fatigue Inventory in a US adult population sample. Popul Health Metr. 2009, 7: 18-10.1186/1478-7954-7-18.CrossRefPubMedCentralPubMedGoogle Scholar
  41. 41.
    Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y: Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther. 2008, 30: 1988-2004. 10.1016/j.clinthera.2008.11.009.CrossRefPubMedGoogle Scholar
  42. 42.
    Arnold LM, Wang F, Ahl J, Gaynor PJ, Wohlreich MM: Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: Secondary analysis of a randomized, placebo-controlled trial. Arthritis Res Ther. 2011, 13: R86-10.1186/ar3359.CrossRefPubMedCentralPubMedGoogle Scholar
  43. 43.
    Owen RT: Milnacipran hydrochloride: its efficacy, safety and tolerability profile in fibromyalgia syndrome. Drugs Today (Barc). 2008, 44: 653-660. 10.1358/dot.2008.44.9.1256003.CrossRefGoogle Scholar
  44. 44.
    Branco JC, Bannwarth B, Failde I, Abello Carbonell J, Blotman F, Spaeth M, Saraiva F, Nacci F, Thomas E, Caubère JP, Le Lay K, Taieb C, Matucci-Cerinic M: Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum. 2010, 39: 448-453. 10.1016/j.semarthrit.2008.12.003.CrossRefPubMedGoogle Scholar
  45. 45.
    Mease PJ, Clauw DJ, Gendreau RM, Rao SG, Kranzler J, Chen W, Palmer RH: The efficacy and safety of milnacipran for treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2009, 36: 398-409. 10.3899/jrheum.080734. A published erratum appears in J Rheumatol 2009, 36:661CrossRefPubMedGoogle Scholar
  46. 46.
    Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE: A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med. 2002, 112: 191-197. 10.1016/S0002-9343(01)01089-0.CrossRefPubMedGoogle Scholar
  47. 47.
    Arnold LM, Gendreau RM, Palmer RH, Gendreau JF, Wang Y: Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010, 62: 2745-2756. 10.1002/art.27559.CrossRefPubMedGoogle Scholar
  48. 48.
    Da Costa D, Dobkin PL, Fitzcharles MA, Fortin PR, Beaulieu A, Zummer M, Senécal JL, Goulet JR, Rich E, Choquette D, Clarke AE: Determinants of health status in fibromyalgia: a comparative study with systemic lupus erythematosus. J Rheumatol. 2000, 27: 365-372.PubMedGoogle Scholar
  49. 49.
    Neumann L, Berzak A, Buskila D: Measuring health status in Israeli patients with fibromyalgia syndrome and widespread pain and healthy individuals: utility of the Short Form 36-item health survey (SF-36). Semin Arthritis Rheum. 2000, 29: 400-408. 10.1053/sarh.2000.7171.CrossRefPubMedGoogle Scholar
  50. 50.
    Tüzün EH, Albayrak G, Eker L, Sözay S, Daşkapan A: A comparison study of quality of life in women with fibromyalgia and myofascial pain syndrome. Disabil Rehabil. 2004, 26: 198-202. 10.1080/09638280310001639696.CrossRefPubMedGoogle Scholar
  51. 51.
    Löwe B, Decker O, Müller S, Brähler E, Schellberg D, Herzog W, Herzberg PY: Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Med Care. 2008, 46: 266-274. 10.1097/MLR.0b013e318160d093.CrossRefPubMedGoogle Scholar
  52. 52.
    Spitzer RL, Kroenke K, Williams JBW, Löwe B: A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006, 166: 1092-1097. 10.1001/archinte.166.10.1092.CrossRefPubMedGoogle Scholar
  53. 53.
    Smarr KL, Keefer AL: Measures of depression and depressive symptoms: Beck Depression Inventory-II (BDI-II), Center for Epidemiologic Studies Depression Scale (CES-D), Geriatric Depression Scale (GDS), Hospital Anxiety and Depression Scale (HADS), and Patient Health Questionnaire-9 (PHQ-9). Arthritis Care Res. 2011, 63: S454-S466. 10.1002/acr.20556.CrossRefGoogle Scholar
  54. 54.
    R: A Language and Environment for Statistical Computing. 2012, R Foundation for Statistical Computing, Vienna, AustriaGoogle Scholar
  55. 55.
    Schaefer C, Chandran A, Hufstader M, Baik R, McNett M, Goldenberg D, Gerwin R, Zlateva G: The comparative burden of mild, moderate and severe fibromyalgia: results from a cross-sectional survey in the United States. Health Qual Life Outcomes. 2011, 9: 71-10.1186/1477-7525-9-71.CrossRefPubMedCentralPubMedGoogle Scholar
  56. 56.
    Walitt B, Fitzcharles MA, Hassett AL, Katz RS, Häuser W, Wolfe F: The longitudinal outcome of fibromyalgia: a study of 1555 patients. J Rheumatol. 2011, 38: 2238-2246. 10.3899/jrheum.110026.CrossRefPubMedGoogle Scholar

Copyright information

© Vincent et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Ann Vincent
    • 1
  • Tanya L Hoskin
    • 2
  • Mary O Whipple
    • 1
  • Daniel J Clauw
    • 3
  • Debra L Barton
    • 4
  • Roberto P Benzo
    • 5
  • David A Williams
    • 3
  1. 1.Division of General Internal MedicineMayo ClinicRochesterUSA
  2. 2.Division of Biomedical Statistics and InformaticsMayo ClinicRochesterUSA
  3. 3.Chronic Pain and Fatigue Research CenterUniversity of Michigan Health SystemAnn ArborUSA
  4. 4.Division of Medical OncologyMayo ClinicRochesterUSA
  5. 5.Division of Pulmonary and Critical Care MedicineMayo ClinicRochesterUSA

Personalised recommendations